Latest News

{{header-clinical-trials-navigation}} FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Condition: Urothelial Carcinoma Intervention: Drug: Pembrolizumab Radiation: SBRT Purpose: This is a feasibility trial of anti-PDL1/PD1 (pembrolizumab) and stereotactic body radiation therapy (SBRT) in patients with advanced, platinum-refractory urothelial carcinoma. Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03287050 […]

{{header-clinical-trials-navigation}} A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer Condition: Urothelial Carcinoma Intervention: Drug: Atezolizumab Drug: Bevacizumab Purpose: This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy. Study Type: Interventional Clinical Trials […]

Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. We aimed to identify the optimal candidates for early SRT after RP. The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received […]

Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 […]

A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in the disease, we performed targeted deep sequencing of tumor and normal DNA from patients with locoregional, metastatic non-castrate, and metastatic castration-resistant […]

Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in practice, clinicians may rely on PSA monitoring alone to determine disease status on therapy. This approach has not been adequately […]

ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Condition: Clear Cell Renal Cell Carcinoma Intervention: Drug: CB-839 plus everolimus Drug: Placebo plus everolimus Purpose: Phase 2 Study Comparing CB-839 in Combination with Everolimus […]

Androgen deprivation therapy (ADT) is a mainstay initial treatment for advanced hormone-sensitive prostate cancer (HSPC), but disease progression to castration-resistant prostate cancer (CRPC) invariably occurs when patients do not succumb to another disease or comorbidity. Recognition that the androgen receptor (AR) axis continues to drive disease progression has led to the development of several AR-directed […]

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN) Condition: Heart Failure, Iron Deficiency, Left Ventricular Systolic Dysfunction Intervention: Drug: Iron (III) isomaltoside 1000 Purpose: This study will address whether the additional use of Intravenous (IV) iron on top of standard care […]

Non-prostatic bed recurrence of prostate cancer (PCa) is usually treated with androgen deprivation therapy (ADT). We analyzed the impact of salvage extended lymph node dissection (sLND) on cancer control in patients with rising PSA and lymph node (LN) metastases. Between 2009 and 2016 we performed sLND in 87 patients with biochemical recurrence (BCR) and positive […]